Oncotarget

Research Papers:

Should all breast cancer patients with four or more positive lymph nodes who underwent modified radical mastectomy be treated with postoperative radiotherapy? A population-based study

Haiyong Wang, Li Kong, Chenyue Zhang, Dawei Chen, Hui Zhu _ and Jinming Yu

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:75492-75502. https://doi.org/10.18632/oncotarget.12260

Metrics: PDF 885 views  |   HTML 989 views  |   ?  


Abstract

Haiyong Wang1,2, Li Kong2, Chenyue Zhang3, Dawei Chen2, Hui Zhu2, Jinming Yu2

1School of Medicine, Shandong University, Jinan, 250012, China

2Department of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences, 250117, China

3Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

Correspondence to:

Hui Zhu, email: drzhuhui@163.com

Jinming Yu, email: sdzlyujinming@126.com

Keywords: breast cancer, mastectomy, radiotherapy, positive lymph nodes, SEER

Received: April 2, 2016     Accepted: September 12, 2016     Published: September 26, 2016

ABSTRACT

Postmastectomy radiotherapy (PMRT) has become a standard adjuvant postoperative therapy for breast cancer patients with four or more positive lymph nodes. However, some studies have demonstrated that some subgroups of the breast cancer patients with four or more positive lymph nodes did not benefit substantially from PMRT. Therefore, it is of great necessity to identify whether all breast cancer patients with four or more positive lymph nodes who underwent modified radical mastectomy be treated with PMRT. In our study, we first established a prognostic model using the Surveillance Epidemiology and End Results (SEER) database between 1998 and 2001. Univariate and multivariate Cox models were used to assess the prognostic factors, and five risk factors individually associated with prognosis including AJCC stage, AJCC T, Grade, ER status, PR status. Prognostic index of PMRT were defined as the number of risk factor (NRF). The NRF scores correlated well with overall survival of PMRT even if the patients were in the sub-poor prognosis group. Then the prognostic model was validated using the SEER database between 2006 and 2009, and the same results were obtained. In conclusion, different from others studies, our study demonstrated that all patients with four or more positive lymph nodes after modified radical mastectomy need to be treated with PMRT ever if the patients belonged to AJCC T4 in a poor prognosis group.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12260